FSD Pharma Inc. announced this week it closed a deal to acquire Prismic Pharmaceuticals, a U.S.-based specialty pharmaceutical company dedicated to addressing the opioid crisis. Through the utilization of its micro-PEA platform, the company seeks to develop novel, non-addictive prescription drugs. Such formulations impact the endocannabinoid system. This means that lower doses of drugs can be used […]